TheraRadar
← Back
Data updated: Jun 28, 2026

ACADIA PHARMS INC

Specialty
Pharmaceuticals Execution: Fair

ACADIA PHARMS INC is a specialty pharmaceutical company with 3 FDA-approved products.

2016
Since
3
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2016-2023)
2 Novel 2 First-in-Class 2 Orphan 1 Breakthrough 2 Priority Review 1 Fast Track
See 2 novel approvals →
2023 DAYBUE (TROFINETIDE) First-in-Class · Orphan · Priority Review · Fast Track
2016 NUPLAZID (PIMAVANSERIN TARTRATE) First-in-Class · Orphan · Breakthrough · Priority Review

ACADIA PHARMS INC at a Glance

  • Fast trial execution (26 months median completion)

ACADIA PHARMS INC's Key Drugs

ACADIA PHARMS INC's core commercial portfolio centers on DAYBUE STIX, DAYBUE — its most strategically important drugs approved in the last 15 years.

DAYBUE STIX
CNS

Rett Syndrome

Approved 2025
DAYBUE
CNS

Rett Syndrome

Approved 2023

ACADIA PHARMS INC's Recent FDA Approvals

ACADIA PHARMS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

DAYBUE STIX NDA
2025-12-11
trofinetide
Rett Syndrome

ACADIA PHARMS INC's Therapeutic Areas

Disease areas where ACADIA PHARMS INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

ACADIA PHARMS INC Pipeline Snapshot

Active clinical trials for ACADIA PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Phase 3 Readout Calendar Pro

4 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q1 2028
ACP-204
Alzheimer's Disease Psychosis
Estimated · fresh NCT06159673
Q1 2029
ACP-204
Lewy Body Dementia Psychosis
Estimated · fresh NCT07095465
Q2 2029
ACP-204
Alzheimer's Disease Psychosis
Estimated · fresh NCT06194799
Unlock 1 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DAYBUE STIX leads revenue
  • • 2 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Active trial monitoring
  • • 4 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 10/17 completed
  • • Speed: 26 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges